

## Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Chun JY, Park S, Jung J, et al. Guillain-Barré syndrome after vaccination against COVID-19. *Lancet Neurol* 2021; published online Dec 17. [https://doi.org/10.1016/S1474-4422\(21\)00416-6](https://doi.org/10.1016/S1474-4422(21)00416-6).

**Supplementary Table 1. Details of clinical and paraclinical findings**

	<b>Case 1</b>	<b>Case 2</b>
<b>Neurological Examination</b>	<p><b>Hospitalization</b></p> <ul style="list-style-type: none"> <li>• Day 0 (Day 5 from the symptom onset)</li> <li>Right upper extremity (Medical Research Council [MRC] grade: proximal, 4/5 and distal, 2/5)</li> <li>Bilateral lower extremities (proximal and distal, 4/5; except dorsiflexion, 1/5)</li> <li>• Day 7</li> <li>Quadripareisis upper &amp; lower (proximal, 4/5 and distal, 1/5)</li> <li>• Day 22</li> <li>Upper (proximal, 4/5 and distal, 2/5) Lower (proximal, 4/5 and distal, 1/5)</li> </ul> <p><b>Outpatient clinic</b></p> <ul style="list-style-type: none"> <li>• Day 42</li> <li>Upper (proximal, 4/5 and distal, 3/5) Lower (proximal, 4/5 and distal, 1/5)</li> </ul>	<p><b>Hospitalization</b></p> <ul style="list-style-type: none"> <li>• Day 0 (Day 40 from the symptom onset)</li> <li>Quadripareisis (upper: proximal, 3/5 and distal, 4/5; lower: proximal, 3/5 and distal, 4/5)</li> <li>• Day 4</li> <li>Upper (proximal, 4/5 and distal, 4/5) Lower (proximal, 3/5 and distal, 4/5)</li> </ul> <p><b>Outpatient clinic</b></p> <ul style="list-style-type: none"> <li>• Day 73</li> <li>Upper (proximal, 4+/5 and distal, 5/5) Lower (proximal, 4+/5 and distal, 4+/5)</li> </ul>
<b>Laboratory Findings</b>	<ul style="list-style-type: none"> <li>• <b>Cerebrospinal fluid analysis:</b> <ul style="list-style-type: none"> <li>- Cell count: 1 lymphocytes/<math>\mu</math>L</li> <li>- Protein level: 43 mg/dL (normal range, 15–45)</li> <li>- CMV PCR: negative</li> <li>- EBV PCR: negative</li> </ul> </li> <li>• <b>SARS-CoV-2 RT-PCR:</b> negative</li> <li>• <b>Blood tests</b> <ul style="list-style-type: none"> <li>- Anti-ganglioside antibodies: negative</li> <li>- Antinuclear antibody: positive (1:320)</li> <li>- Antineutrophilic cytoplasmic antibody: negative</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• <b>Cerebrospinal fluid analysis:</b> <ul style="list-style-type: none"> <li>- Cell count: 2 lymphocytes/<math>\mu</math>L</li> <li>- Protein level: 61 mg/dL (normal range, 15–45)</li> <li>- CMV PCR: negative</li> <li>- EBV PCR: negative</li> </ul> </li> <li>• <b>SARS-CoV-2 RT-PCR:</b> negative</li> <li>• <b>Blood tests</b> <ul style="list-style-type: none"> <li>- Anti-ganglioside antibodies: negative</li> <li>- Antinuclear antibody: negative</li> <li>- Antineutrophilic cytoplasmic antibody: negative</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>- Complement 3 level: 79·67 mg/dL (normal range, 90–180)</li> </ul>	<ul style="list-style-type: none"> <li>- Complement levels: unremarkable</li> </ul>
<b>Brighton criteria</b>	<p><u>Level 2 of diagnostic certainty</u></p> <ul style="list-style-type: none"> <li>• Bilateral and flaccid weakness of limbs</li> <li>• Decreased or absent deep tendon reflexes in weak limbs</li> <li>• Monophasic course and time between onset-nadir 12 hours to 28 days</li> <li>• CSF cell count &lt; 50/<math>\mu</math>L</li> <li>• NCS findings consistent with one of the subtypes of GBS</li> <li>• Absence of alternative diagnosis for weakness</li> </ul>	<p><u>Level 1 of diagnostic certainty</u></p> <ul style="list-style-type: none"> <li>• Bilateral and flaccid weakness of limbs</li> <li>• Decreased or absent deep tendon reflexes in weak limbs</li> <li>• Monophasic course and time between onset-nadir 12 hours to 28 days</li> <li>• CSF cell count &lt; 50/<math>\mu</math>L</li> <li>• CSF protein level &gt; normal value</li> <li>• NCS findings consistent with one of the subtypes of GBS</li> <li>• Absence of alternative diagnosis for weakness</li> </ul>

CMV; cytomegalovirus, EBV; Epstein-Barr virus, SARS-CoV-2; severe acute respiratory syndrome coronavirus-2, RT-PCR; reverse transcription polymerase chain reaction, NCS; nerve conduction study, GBS; Guillain–Barré syndrome

**Supplementary Table 2. Neurophysiological (NP) findings of the patients. The protocol included bilateral motor median, ulnar, peroneal, and tibial nerves; sensory median, ulnar, peroneal, and sural nerves; bilateral F wave latency of median, ulnar, peroneal, and tibial nerves. The patient 1 was classified as the axonal variant; the patient 2 as the demyelinating type with prolonged latencies and decreased conduction velocity.**

Table 2-1. Patient 1 – Initial study (6 days after the symptom onset)

	Distal latency, ms	Amplitude, mV	Conduction velocity, m/s	F latency, ms
Motor				
Right median nerve				
Wrist	3.4 (nl ≤ 3.6)	0.7 (nl ≥ 5)	-	Absent F (nl ≤ 26.9)
Elbow	7.5	0.6	51.2 (nl ≥ 49.9)	-
Axilla	9.6	0.3	52.3 (nl ≥ 55.9)	-
Right ulnar				
Wrist	2.8 (nl ≤ 2.5)	0.4 (nl ≥ 5)	-	Absent F (nl ≤ 26.6)
Elbow	7.2	0.3	47.7 (nl ≥ 50.6)	-
Axilla	9.6	0.2	50.0 (nl ≥ 52.7)	-
Right tibial				
Ankle	4.7 (nl ≤ 5.1)	1.6 (nl ≥ 5)	-	Absent F (nl ≤ 47.4)
Popliteal fossa	14.0	0.5	27.9 (nl ≥ 40.6)	-
Left tibial				
Ankle	6.2 (nl ≤ 5.1)	1.6 (nl ≥ 5)		Absent F (nl ≤ 47.4)
Popliteal fossa	12.6	0.3	45.3 (nl ≥ 40.6)	-
Right peroneal				
Ankle	NR (nl ≤ 4.8)	NR (nl ≥ 4)	-	Absent F (nl ≤ 44.9)
Knee	NR	NR	- (nl ≥ 41.9)	-
Left peroneal				
Ankle	5.4 (nl ≤ 4.8)	0.3 (nl ≥ 4)	-	Absent F (nl ≤ 44.9)
Knee	12.0	0.2	33.3 (nl ≥ 41.9)	-
Sensory				
Right sural	3.0 (nl ≤ 3.1)	6.9 (nl ≥ 6)	33.3 (nl ≥ 34.6)	-
Left sural	3.1 (nl ≤ 3.1)	8.7 (nl ≥ 6)	32.4 (nl ≥ 34.6)	-
EMG				
Not done				

\*NL: normal value, NR: no response

Table 2-2. Patient 1 – Follow-up study (17 days after the symptom onset)

	Distal latency, ms	Amplitude, mV	Conduction velocity, m/s	F latency, ms
<b>Motor</b>				
<b>Right median nerve</b>				
Wrist	NR (nl ≤ 3.6)	NR (nl ≥ 5)	-	Absent F (nl ≤ 26.9)
Elbow	NR	NR	- (nl ≥ 49.9)	-
Axilla	NR	NR	- (nl ≥ 55.9)	-
<b>Right ulnar</b>				
Wrist	NR (nl ≤ 2.5)	NR (nl ≥ 5)	-	Absent F (nl ≤ 26.6)
Elbow	NR	NR	- (nl ≥ 50.6)	-
Axilla	NR	NR	- (nl ≥ 52.7)	-
<b>Right tibial</b>				
Ankle	NR (nl ≤ 5.1)	NR (nl ≥ 5)	-	Absent F (nl ≤ 47.4)
Popliteal fossa	NR	NR	- (nl ≥ 40.6)	-
<b>Left tibial</b>				
Ankle	NR (nl ≤ 5.1)	NR (nl ≥ 5)		Absent F (nl ≤ 47.4)
Popliteal fossa	NR	NR	- (nl ≥ 40.6)	-
<b>Right peroneal</b>				
Ankle	NR (nl ≤ 4.8)	NR (nl ≥ 4)	-	Absent F (nl ≤ 44.9)
Knee	NR	NR	- (nl ≥ 41.9)	-
<b>Left peroneal</b>				
Ankle	NR (nl ≤ 4.8)	NR (nl ≥ 4)	-	Absent F (nl ≤ 44.9)
Knee	NR	NR	- (nl ≥ 41.9)	-
<b>Sensory</b>				
Right sural	NR (nl ≤ 3.1)	NR (nl ≥ 6)	- (nl ≥ 34.6)	-
Left sural	NR (nl ≤ 3.1)	NR (nl ≥ 6)	- (nl ≥ 34.6)	-
<b>EMG</b>	Denervation potentials on deltoid, vastus lateralis, abductor pollicis brevis, tibialis anterior & thoracic para-spinal (T 4,5,7) muscles			

\*NL: normal value, NR: no response

Table 2-3. Patient 2 – Initial study (40 days after the symptom onset)

	Distal latency, ms	Amplitude, mV	Conduction velocity, m/s	F latency, ms
<b>Motor</b>				
<b>Right median nerve</b>				
Wrist	5.6 (nl ≤ 3.6)	6.9 (nl ≥ 5)	-	36.9 (nl ≤ 26.9)
Elbow	10.1	6.2	44.4 (nl ≥ 49.9)	-
Axilla	12.2	6.0	52.3 (nl ≥ 55.9)	-
<b>Right ulnar</b>				
Wrist	3.1 (nl ≤ 2.5)	10.9 (nl ≥ 5)	-	29.1 (nl ≤ 26.6)
Elbow	7.3	10.7	47.6 (nl ≥ 50.6)	-
Axilla	9.5	10.2	54.5 (nl ≥ 52.7)	-
<b>Right tibial</b>				
Ankle	5.1 (nl ≤ 5.1)	14.1 (nl ≥ 5)	-	55.9 (nl ≤ 47.4)
Popliteal fossa	13.6	8.0	32.9 (nl ≥ 40.6)	-
<b>Left tibial</b>				
Ankle	6.3 (nl ≤ 5.1)	17.8 (nl ≥ 5)		48.6 (nl ≤ 47.4)
Popliteal fossa	14.0	16.4	36.3 (nl ≥ 40.6)	-
<b>Right peroneal</b>				
Ankle	6.2 (nl ≤ 4.8)	3.2 (nl ≥ 4)	-	56.8 (nl ≤ 44.9)
Knee	12.2	2.8	40.0 (nl ≥ 41.9)	-
<b>Left peroneal</b>				
Ankle	7.2 (nl ≤ 4.8)	1.0 (nl ≥ 4)	-	55.3 (nl ≤ 44.9)
Knee	14.7	0.9	29.3 (nl ≥ 41.9)	-
<b>Sensory</b>				
Right sural	3.9 (nl ≤ 3.1)	9.7 (nl ≥ 6)	30.7 (nl ≥ 34.6)	-
Left sural	3.7 (nl ≤ 3.1)	8.1 (nl ≥ 6)	32.0 (nl ≥ 34.6)	-
<b>EMG</b>				
Not done				

\*NL: normal value, NR: no response